Letterkenny

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.

Researchers are evaluating if Negative Pressure Wound Therapy (NPWT) dressings can reduce surgical site infections, post-surgical complications, and improve scar appearance compared to standard wound dressings in patients undergoing abdominal surgery through a midline laparotomy. The study addresses the significant impact of wound complications after abdominal surgery, which can delay recovery, increase hospital stay, and raise healthcare costs. Limited data exists on the use of NPWT for laparotomy incisions, so this trial aims to provide evidence for its effectiveness and cost implications in both acute and elective surgical settings. The study compares two groups: one receiving NPWT dressings applied to the surgical wound after laparotomy and the other receiving standard wound dressings. NPWT dressings work by removing and absorbing fluid leaking from the wound, potentially improving healing and scar outcomes. Both treatments are applied after the surgical procedure. The trial includes evaluation periods at 1, 3, and 6 months after surgery to monitor wound healing and infection rates. Participants will be involved in follow-up assessments including monitoring for surgical site infections at multiple time points after surgery. Researchers will also collect data on wound healing, scar appearance, and patient quality of life through questionnaires. The study will include a cost analysis to understand the economic impact of using NPWT dressings. Overall participation covers the immediate post-operative period and extends through 6 months of follow-up to capture both short- and longer-term outcomes.

Researchers are evaluating targeted therapies for adult participants with moderate to severe Crohn's disease, a chronic condition causing severe inflammation in the digestive tract. This disease often leads to symptoms like belly pain, diarrhea, tiredness, and weight loss. The study aims to assess the effectiveness and side effects of several targeted treatments, as current therapies may not work equally well for all patients or may lose effectiveness over time. This is a Phase 2a multicenter, randomized platform study enrolling around 540 adults across approximately 300 sites worldwide. The treatments being studied include risankizumab, trosunilimab, lutikizumab, and ABBV-8736. These therapies are administered either as injections under the skin or infusions into the vein, depending on the drug. Participants will be randomly assigned to one of the treatment groups. The study will involve regular visits to hospitals or clinics where participants receive their assigned treatments and are monitored throughout the study period. Participants will undergo medical assessments including blood tests and endoscopies to check the status of their disease and to monitor for any side effects. They will also complete questionnaires and keep a daily diary to track their condition. The main outcome measured is the percentage of participants who achieve endoscopic remission by week 12. The study involves careful safety monitoring and aims to provide detailed data on the treatments over the course of the trial.

Researchers are evaluating the safety and effectiveness of MTX-463, an immunoglobin G1 monoclonal antibody targeting WISP1, in people with idiopathic pulmonary fibrosis (IPF). This Phase 2a randomized, double-blind, placebo-controlled study includes participants aged 40 years and older who meet specific diagnostic criteria and may be using approved IPF treatments such as pirfenidone or nintedanib. The study aims to measure changes in forced vital capacity (FVC) over 24 weeks to assess MTX-463's impact on lung function. Participants will be randomly assigned to receive either MTX-463 or a placebo through intravenous infusions every four weeks from Day 0 to Week 20. The treatment period concludes with an End of Treatment Visit at Week 24, followed by a Safety Follow-Up Visit at Week 28. Blood samples will be collected regularly to monitor safety, WISP1 levels, and drug presence, while lung function tests including FVC and lung perfusion imaging will be performed at set intervals. During the study, participants will visit the clinic for assessments at screening, baseline, and throughout the treatment and follow-up periods. These assessments include lung function tests, safety labs, and evaluation of treatment effects. Researchers will monitor participants closely to understand MTX-463's safety profile and its effect on lung function in IPF over the full 28 weeks of participation.